Clinical Trials
10 trialsNCT06634589 2026-05-11
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
Phase 1/2 Recruiting
NCT05896163 2026-05-06
MAPtivate-6
Pfizer
Phase 1/2 Terminated
NCT05533775 2026-05-04
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03075696 2026-04-30
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06090539 2026-04-14
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT03533283 2026-04-06
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04077723 2026-03-02
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT05861050 2026-02-19
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Recruiting
NCT06357676 2026-01-30
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT04914741 2024-08-12
COALITION
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting